CatSci's Acquisition Of Reach Separations Sets New Industry Standard

CatSci Ltd, an innovation partner in the field of medicines development, has successfully acquired Reach Separations. Reach Separations is renowned for its expertise in chromatography, particularly in the analysis and purification of therapeutics. This acquisition was made possible with the backing of Keensight Capital, a private equity firm specializing in pan-European Growth Buyout investments.

Reach Separations, headquartered in the UK and operating laboratories in both the UK and France, excels in chromatography services for both chiral and achiral therapeutics. Known for its distinctive analytical capabilities and a highly skilled team, Reach Separations is a preferred partner for delivering a range of purification projects, from discovery chromatography to large-scale Supercritical Fluid Chromatography (SFC) for chiral purification and impurity isolation.

The acquisition of Reach will allow CatSci to offer its global clientele comprehensive chromatographic services that support every stage from discovery to manufacturing. These services can be integrated into full asset development or utilized for standalone projects. With this expanded separation science capability, CatSci will deliver high-quality analyses for small molecules, oligonucleotides, and other complex synthetic medicines.

Reach’s advanced SFC (Supercritical Fluid Chromatography) and HPLC (High-Performance Liquid Chromatography) equipment offers a variety of screening options and problem-solving solutions, enhancing the support provided to the combined company’s customers. This acquisition represents a pivotal step in CatSci’s growth strategy, strengthening its CMC (Chemistry, Manufacturing, and Controls) capabilities and adding strategic value to its customer partnerships.

“We are excited to welcome Reach Separations into the CatSci Group. The need for solving complex analytical problems while meeting the ever-evolving regulatory demands is growing alongside the development of new modalities, such as oligonucleotides, TACs (Targeting Chimeras), and glues. Joining forces with Reach gives our customers access to end-to-end coverage of the analytical development lifecycle, taking them from discovery through to GMP manufacture, and ultimately enabling them to help patients in need”, said Dr. Ross Burn, CEO of CatSci.

Peter Ridgway, Business Development Director at Reach Separations, further commented “Becoming part of the CatSci Group will enhance and strengthen Reach Separations’ ability to deliver excellence in chromatography. Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset. As one of the founders of Reach Separations, I am delighted to join forces with CatSci to deliver strong growth and expand separation science into new marketplaces.”